JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ciuffo, G. M.
Right arrow Articles by Saavedra, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ciuffo, G. M.
Right arrow Articles by Saavedra, J. M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH

Selective peptide and nonpeptide ligands differentially bind to angiotensin II AT2 receptor and a non-angiotensin II CGP42112 binding site

GM Ciuffo and JM Saavedra

Section on Pharmacology, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.

[125I]CGP42112 [Nic-Tyr-(epsilon-CBZ (benzyloxycarbonyl)-Arg)Lys-His- Pro-Ile] does not only recognize angiotensin II AT2 receptors, but has also the capacity to label a high-affinity, non-angiotensin II binding site, selectively associated with macrophages and activated microglia. We have searched for the structural requirements of the novel CGP42112 binding site, and compared these with the requirements for binding to the angiotensin II AT2 site. We designed a series of CGP42112 analogs and evaluated the new compounds by using binding assays on rat spleen (CGP42112 site) and rat fetal (angiotensin II AT2 site) membranes. The non-peptidic analog Z-Arg(Pmc)OH (N alpha CBZ-NG-2,2,5,7,8- pentamethylchroman-6-sulphonyl-L-Arg), the side chain of CGP42112 substituted on the guanidinium group, was selective in recognizing the CGP42112 site, and did not displace binding from the angiotensin II AT2 site. This is a potential lead compound for development of CGP42112 site-selective analogs. Conversely, the CGP42112 analog lacking the CBZ- group (Nic-Tyr-(Ac-Arg)Lys-His-ProOH, III) and the peptide Nic-Tyr-Lys- His-Ala-HisOH (VI), were selective for the angiotensin II AT2 site, and recognized the CGP42112 site poorly. Our results demonstrate that the structural requirements for the nonangiotensin II CGP42112 and the angiotensin II AT2 binding sites are different. We propose that the CBZ group and the free carboxyl terminal group, together with their spatial orientation, are key components of the molecule for the interaction in the non-angiotensin CGP42112 binding pocket.

Volume 274, Issue 3, pp. 1129-1134, 09/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1995 by the American Society for Pharmacology and Experimental Therapeutics.